DEENOVA
Deenova, the Franco-Italian group and Europe's leading provider of medication safety automation solutions for hospitals and long-term care facilities, is pleased to announce the signing of two new contracts for the supply of its latest range of AIDE automated systems.
The first contract was signed with the Charles Perrens Hospital in Bordeaux to supply the AIDE-CUT, Deenova's drug safety automation system for tablet cutting and repackaging of all types of drugs. When repackaging unit dose medications, the AIDE-CUT ensures maximum accuracy and safety. The system is outfitted with high-tech sensors that detect and correct errors in real time, ensuring that the cutting and repackaging processes are optimized.
The second contract was signed with the Paul Reig Retirement Home in Banyuls, France, for the supply of the AIDE-PICK, Deenova's personalized therapy preparation automation system for the distribution of treatments to patients. The AIDE-PICK improves patient safety, reduces medication errors, and maximizes operational efficiency by ensuring full medication traceability, allowing nurses to spend more time with patients and less time preparing therapies.
Initially launched in 2013, the AIDE line of automated dispensers has been updated over the course of 2022-2023 to integrate modules that allow for the automatic repackaging and dispensing of all forms of medication, including sachets, ampoules, pre-filled syringes and vials. The new AIDE line will be presented at the French-speaking hospital pharmacy congress Hopipharm, which will be held this year from May 24 to 26 at the Strasbourg Congress Centre (Stand 79).
“These contracts are a testament to our customers' confidence in our ability to provide innovative and reliable solutions that improve the safety and efficiency of medication management,” said Loїc Bessin, AIDE solutions designer and managing director of Deenova France, adding, “With less than a year after the launch of our AIDE line, we already have six installations planned for 2023.”
With these two new contracts, Deenova reinforces its leadership position in the French medication safety automation market, as Christophe Jaffuel, member of the Board of Directors and Chief Commercial Officer of the Deenova Group, explains: “After 10 years of leadership in the French market with the ACCED automated system, the successful launch of our new AIDE modular range is very promising for the future of our company.”
About Deenova
Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.
For more information on Deenova’s market-leading solutions, visit www.deenova.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005708/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202512.5.2025 14:23:00 CEST | Press release
All economic and financial indicators grew:Consolidated revenues of €603.4 million (€554.3 million in 2024);EBITDA of €105.3 million (€87.3 million in 2024);EBIT of €88.7 million (€72.1 million in 2024);Profit before tax amounts to €86.9 million (€73.1 million in 2024). Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2025. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €603.4 million, an increase of 8.9% compared to the corresponding data for 2024. All indicators are positive for the period. In the first quarter of 2025 the consolidated EBITDA was €105.3 million compared to €87.3 million in 2024, equal to 17.5% of the turnover. EBIT, from January to March, was €88.7 million (€72.1 million in 2024) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €86.9 million (€73.1 million in 2024), equal to 14.4% of the turnover. The net financial position of the Gr
Adtran boosts DCI capabilities with dynamic AI Network Cloud solution12.5.2025 14:00:00 CEST | Press release
News summary: Hyperscalers, federal, SLED and enterprise customers need to expand AI services while managing high-performance data transport demands Adtran’s enhanced AINC-interconnect solution integrates with Dell’s AI Factory to optimize AI workloads and enable seamless scaling Solution delivers up to 50x performance acceleration, 20% GPU utilization efficiencies and 50% transport savings Adtran today announced its new AI Network Cloud (AINC)-interconnect solution, a next-generation fiber networking platform designed to support hyperscalers, federal agencies, SLED organizations and enterprises as they scale AI services. Integrating with Dell’s AI Factory, the technology dynamically adjusts optical networking capacity to meet real-time AI workloads, enabling seamless, high-speed connectivity from data center to data center and from core to edge. By supporting tokenized, sovereign AI networks and dynamic compute allocation, the solution empowers organizations to scale AI initiatives wi
HistoSonics Secures First Major Insurance Coverage for Non-Invasive Histotripsy Treatment for Liver Tumors With Blue Cross Blue Shield of Michigan12.5.2025 14:00:00 CEST | Press release
Non-Invasive Histotripsy for Liver Tumors Now Reimbursed for 4.5 Million Residents Across Michigan HistoSonics, the developer of the Edison Histotripsy System, today announced that Blue Cross Blue Shield of Michigan (BCBSM) and Blue Care Network have created a new medical policy for histotripsy of the liver. The policy covers non-thermal histotripsy using the Edison® Histotripsy System for the treatment of primary and metastatic liver tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512714050/en/ HistoSonics Edison Histotripsy System As of February 1, 2025, histotripsy is a reimbursable procedure for the non-invasive mechanical destruction of liver tumors under CPT code 0686T, giving eligible patients in Michigan early access to this groundbreaking, non-invasive, incisionless treatment ahead of the broader policy effective date of July 1, 2025. “Liver tumors are often a leading cause of death for patients with serio
Rochon Genova: Did You Purchase Shares of Aphria Inc. (“Aphria”) After January 29, 2018 and Hold Them Until March 23, 2018 and/or December 3, 2018?12.5.2025 14:00:00 CEST | Press release
A Settlement has been reached in the global class action against Aphria and certain of its former officers and directors regarding alleged misrepresentations made in certain of Aphria’s public disclosures released between January 29, 2018 and December 3, 2018 (the “Class Action”). Aphria and the other Defendants have denied all allegations against them. The Settlement provides for the payment by the Defendants of the total amount of CAD $30,000,000 to resolve the Class Action. The Settlement is a compromise of disputed claims and is not an admission of liability or wrongdoing by the Defendants. The Settlement has been approved by the Ontario Superior Court of Justice. The Court has appointed RicePoint Administration, Inc., d/b/a Verita Global as the Administrator of the Settlement. To be eligible for compensation, Class Members must submit a completed Claim Form to the Administrator no later than August 26, 2025. If you do not file a claim by this deadline, you will be ineligible for c
Kinaxis Supercharges BayWa r.e. Solar Trade’s Supply Chain with AI-Powered Orchestration12.5.2025 13:00:00 CEST | Press release
Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, announced that BayWa r.e. Solar Trade, one of the world’s largest distributors of photovoltaic components, has implemented its AI-powered orchestration platform Maestro™ to enhance decision-making, improve resilience and scale operations. As global supply chains face increasing disruptions, BayWa r.e. Solar Trade needed a more agile, data-driven solution to maintain efficiency, meet growing demand and adapt to increasing complexities all while ensuring long-term scalability. BayWa r.e. Solar Trade was looking for a supply chain planning solution that could keep pace with its rapid expansion and growing operational complexity. Traditional Enterprise Resource Planning (ERP) systems couldn’t provide the agility required, leading to visibility gaps and slower decision-making. To scale efficiently and stay ahead of disruptions, the company turned to Maestro to accelerate planning, reduce complexity, and improve re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom